CASI

CASI Pharmaceuticals, Inc. (CASI) | Rumor.io

CASI Pharmaceuticals

CASI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CASI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Feb 26

CASI Pharmaceuticals, Inc. ($CASI) has been delisted from NASDAQ and will begin trading on the OTC under the ticker $CASIF.
The stock has experienced a significant price drop, down 60%+, and is currently trading at around $0.20 per share.
The delisting and potential re-rating of the stock have led some to speculate that it may experience a significant price increase in the near future.

Generated by AI

Sentiment

Of the messages about CASI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.7% +17.63
Bearish	—	—	—	9.3% -17.63

Bullish· Aug 15

$CASI has shown significant price growth, with a 111% surge in one month following the FDA's IND approval for CID-103.
The stock has seen increased buying power, with a potential for further price increases as investors take notice of its upward trend.
$CASI has been identified as a strong candidate for a short squeeze, with its price breaking $3 and showing signs of high volatility.

Bearish· Aug 4

The stock has dropped significantly, with some traders considering it a "brutal drop" and others calling it a "crazy drop".
The asset's price has declined to levels that some traders consider a "bitch" and a "scam", with one user even calling it a "100% move".
The stock's volume has not been strong, with one trader noting that it has been "just slowing diluting" at a certain price range.

Generated by AI

Topics

Of the messages about CASI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	27.97%
Announcements	—	—	—	11.54%
Controversies	—	—	—	0.66%
Earnings	—	—	—	0.07%
Macro	—	—	—	27.64%
Technical Analysis	—	—	—	32.12%

Earnings· Mar 29

CASI Pharmaceuticals, Inc. reported a Q4 loss of $0.08 per share, missing consensus estimates of a loss of $0.03.
The company's Q4 earnings per share (EPS) loss was $0.08.
CASI Pharmaceuticals' Q4 EPS result was a miss, with the company reporting a loss that was wider than expected.

Announcements· Aug 5

CASI Pharmaceuticals' stock price increased by 51.16% after FDA clearance for a transplant drug.
CASI Pharmaceuticals announced FDA clearance for a transplant drug, which led to a significant increase in its stock price.
The company filed a Form 6-K with the SEC, disclosing the FDA clearance and acceptance of the press release.

Technical Analysis· Aug 23

CASI Pharmaceuticals, Inc. ($CASI) is showing a potential breakout with a strong upward movement predicted if it can pass $1.62.
The stock is setting up for continuation, with a head and shoulders pattern on the 5-minute chart potentially leading to a drop to $1.32.
The Relative Strength Index (RSI) is a bit high for the 5-day period, indicating possible overbought conditions and a potential reversal.

Generated by AI

Community

Of the messages about CASI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	17.77%
Newcomers	—	—	100%	82.23%

Regulars· Jun 27

Three key points about CASI Pharmaceuticals, Inc. are:
The company plans to submit an IND application for CID-103.
A non-binding proposal has been received to acquire CASI's entire China business.

Newcomers· Aug 4

New users are focused on the potential for a clearout, expecting it to happen either at the end of the day or after hours.
Some newcomers are watching the stock for potential parabolic continuation, anticipating major volatility and encouraging users to be mindful of their risk-to-reward ratio.
The FDA clearance for CASI Pharmaceuticals' transplant drug is a significant development, leading to a surge in the stock's price.

Generated by AI

Also Discussed

Investors talking about CASI also mention

#	Name	Attention
1	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
2	Daxor CorporationDXR	0%0
3	SemiLEDs CorporationLEDS	0%0
4	Recon Technology, Ltd. Class A Ordinary SharesRCON	0%0
5	Can-Fite BioPharma Ltd. ADRCANF	0%0
6	Arcadia Biosciences Inc.RKDA	0.01%0
7	SGRP - SPAR Group, Inc.	——
8	Avalon Holdings Corp. Class A Common StockAWX	0%new
9	AB Corporate Bond ETFEYEG	0%0
10	GRCL - Gracell Biotechnologies Inc.	——